Acquiring Company
Otsuka America
Acquired Company
Transcend Therapeutics
PrincetonNew YorkBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareMedicalTherapeuticsDescription
Otsuka America, Inc. has completed its acquisition of Transcend Therapeutics for $700 million, with additional contingent payments based on future sales. Transcend will operate as a wholly owned subsidiary, enhancing Otsuka’s investment in neuropsychiatric treatments. This acquisition aims to accelerate the development of innovative therapies for serious mental illnesses like PTSD.
Quick answer
Otsuka America is acquiring Transcend Therapeutics for $700 million, announced June 12, 2026. Otsuka America is based in Princeton, New Jersey, United States.
- How much did Otsuka America pay for Transcend Therapeutics?
- The reported deal value is $700 million.
- What does Otsuka America do?
- Otsuka America, Inc. is a subsidiary of Otsuka Pharmaceutical Co., Ltd. It focuses on advancing next-generation treatments for serious mental illness.
- Where are Otsuka America and Transcend Therapeutics based?
- Otsuka America is based in Princeton, New Jersey, United States. Transcend Therapeutics is based in New York, United States.
- Who are the decision-makers at Otsuka America?
- Fundz holds 1 contact at Otsuka America. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Medical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Scipher Medicine to merge with Chemomab Therapeutics (July 8, 2026)
- Chemomab to acquire Scipher Medicine Corporation (July 7, 2026)
- Hemant Surgical to acquire Lifesenz for ₹19.99 crore (May 27, 2026)
- Yarrow Bioscience completes merger with VYNE Therapeutics (July 27, 2026)
- Neuphoria Therapeutics to acquire Scancell Holdings (July 24, 2026)
- Scancell to acquire Neuphoria in all-share merger (July 23, 2026)
Who to call at Otsuka America, and when
When Otsuka America changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Otsuka America raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Otsuka America, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Otsuka America. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Otsuka America makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Transcend Therapeutics?
Transcend Therapeutics was acquired by Otsuka America, based in Princeton. The deal was reported on June 12, 2026. Otsuka America, Inc. is a subsidiary of Otsuka Pharmaceutical Co., Ltd. It focuses on advancing next-generation treatments for serious mental illness. Otsuka America is privately held and operates in Biotechnology.
When did Otsuka America acquire Transcend Therapeutics?
Otsuka America's acquisition of Transcend Therapeutics was reported on June 12, 2026. Otsuka America, Inc. has completed its acquisition of Transcend Therapeutics for $700 million, with additional contingent payments based on future sales. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Transcend Therapeutics do?
Transcend Therapeutics discovers, develops, and delivers next-generation psychoactive medicines to work toward a world in which people no longer suffer from neuropsychiatric disease. It is privately held, operating in Biotechnology, and is based in New York.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.